null Option on ProPhase Labs
| PRPH Stock | USD 0.40 0.03 8.11% |
ProPhase Labs' latest option contracts expiring on October 17th 2025 are carrying combined implied volatility of 1.37 with a put-to-call open interest ratio of 0.03 over 14 outstanding agreements suggesting investors are buying way more calls than puts on contracts expiring on October 17th 2025.
Open Interest Against October 17th 2025 Option Contracts
2025-10-17
The chart above shows ProPhase Labs' distribution of open interest by maturity on contracts that have not yet been settled. The area between the two highest points is the projection of the price at expiration. ProPhase Labs' open interest chart also provides vital information regarding the liquidity of an option. If there is no open interest for ProPhase Labs' option, there is no secondary market available for investors to trade.
In The Money vs. Out of Money Option Contracts on ProPhase Labs
Analyzing ProPhase Labs' in-the-money options over time can help investors to take a profitable long position in ProPhase Labs regardless of its overall volatility. This is especially true when ProPhase Labs' options are deep in the money. These options can be identified using deltas that are over 0.75. Deep in-the-money ProPhase Labs' options could be used as guardians of the underlying stock as they move almost dollar for dollar with ProPhase Labs' stock while costing only a fraction of its price.
ProPhase Current Options Market Mood
ProPhase Labs' open interest and total value indicators provide investors with the necessary information to digest the overall options buildup for its expiring contracts. In addition, it helps ProPhase Stock's traders understand whether a recent fall or rise in the market is unreasonable and if the time has come to take contrarian positions. These ratios are calculated based on options trading volumes and current open interest.
Put-to-Call Open Interest
Put-to-Call Volume
Unfortunately, most ProPhase Labs' options investors are not very successful. ProPhase Labs' option open interest and volume spread between outstanding puts and calls are regarded by many investors as reliable indicators of the overall future market direction.
Rule 16 of the current ProPhase contract
Base on the Rule 16, the options market is currently suggesting that ProPhase Labs will have an average daily up or down price movement of about 0.0856% per day over the life of the 2025-10-17 option contract. With ProPhase Labs trading at USD 0.40000001, that is roughly USD 3.43E-4. If you think that the market is fully incorporating ProPhase Labs' daily price movement you should consider buying ProPhase Labs options at the current volatility level of 1.37%. But if you have an opposite viewpoint you should avoid it and even consider selling them.
Purchasing ProPhase Labs options can give investors a meaningful hedge against losses and, therefore, could be used conservatively to decrease the volatility of your portfolio. However, many options could also amount to little more than gambling, significantly enhancing your overall portfolio risk. One simple example of these aggressive strategies is the sale of "uncovered" ProPhase calls. Remember, the seller must deliver ProPhase Labs stock to the call owner when a call is exercised.
ProPhase Labs Option Chain
When ProPhase Labs' strike price is surpassing the current stock price, the option contract against ProPhase Labs stock is said to be in the money. When it comes to buying options that are ITM or OTM, the choice depends on your outlook for the underlying security, financial situation, and what you are trying to achieve.
ProPhase Labs' option chain is a display of a range of information that helps investors for ways to trade options on ProPhase. In general, an option chain provides a helpful tool for investors to see all available option contracts, both puts, and calls, for ProPhase. It also shows strike prices and maturity days for a ProPhase Labs against a given expiration period. The table below combines all the option information in the form of a chain but before you use it, remember that it entails significant risk and it is not for everyone. | Open Int | Strike Price | Current Spread | Last Price | |||
Call | PRPH251017C00007500 | 0 | 7.5 | 0.0 - 0.75 | 0.75 | |
Call | PRPH251017C00005000 | 0 | 5.0 | 0.0 - 0.75 | 0.75 | |
Call | PRPH251017C00002500 | 285 | 2.5 | 0.0 - 0.75 | 0.75 | Out |
Call | PRPH251017C00002000 | 0 | 2.0 | 0.0 - 0.85 | 0.85 | |
Call | PRPH251017C00001500 | 0 | 1.5 | 0.0 - 0.85 | 0.85 | |
Call | PRPH251017C00001000 | 191 | 1.0 | 0.0 - 0.05 | 0.05 | Out |
Call | PRPH251017C00000500 | 1298 | 0.5 | 0.05 - 0.1 | 0.05 | Out |
Put | PRPH251017P00000500 | 51 | 0.5 | 0.0 - 0.2 | 0.16 | In |
Put | PRPH251017P00001000 | 1 | 1.0 | 0.6 - 0.75 | 0.6 | In |
Put | PRPH251017P00001500 | 0 | 1.5 | 0.65 - 1.5 | 0.65 | In |
Put | PRPH251017P00002000 | 0 | 2.0 | 1.1 - 2.0 | 1.1 | In |
Put | PRPH251017P00002500 | 0 | 2.5 | 2.0 - 2.2 | 2.0 | In |
Put | PRPH251017P00005000 | 0 | 5.0 | 4.6 - 4.9 | 4.6 | In |
Put | PRPH251017P00007500 | 0 | 7.5 | 6.7 - 7.2 | 6.7 | In |
ProPhase Labs Selling And Marketing Expenses Over Time
Selling And Marketing Expenses |
| Timeline |
ProPhase Total Stockholder Equity
Total Stockholder Equity |
|
ProPhase Labs Corporate Management
| Billy White | Consultant | Profile | |
| Lance Bisesar | Corporate Controller | Profile | |
| Robert Morse | Principal Controller | Profile | |
| Stu Hollenshead | Chief Officer | Profile | |
| Sergio Miralles | Executive Diagnostics | Profile | |
| Kamal Obbad | Senior Genomics | Profile |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in ProPhase Labs. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. For more detail on how to invest in ProPhase Stock please use our How to Invest in ProPhase Labs guide.You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ProPhase Labs. If investors know ProPhase will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ProPhase Labs listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.95) | Earnings Share (2.23) | Revenue Per Share | Quarterly Revenue Growth (0.39) | Return On Assets |
The market value of ProPhase Labs is measured differently than its book value, which is the value of ProPhase that is recorded on the company's balance sheet. Investors also form their own opinion of ProPhase Labs' value that differs from its market value or its book value, called intrinsic value, which is ProPhase Labs' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ProPhase Labs' market value can be influenced by many factors that don't directly affect ProPhase Labs' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ProPhase Labs' value and its price as these two are different measures arrived at by different means. Investors typically determine if ProPhase Labs is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ProPhase Labs' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.